… Resistance to gemcitabine and other chemotherapeutic drugs is an essential factor in this
failure. This review analyzes the molecular causes of gemcitabine resistance … in pancreatic …

… Resistance to gemcitabine is the main challenge of chemotherapy for pancreatic ductal
adenocarcinoma … Hence, the development of a response signature to gemcitabine is essential for …

… of CD73 in pancreatic ductal adenocarcinoma (PDAC). Our findings support that the elevated
expression of CD73 in PDAC cells promotes gemcitabine (GEM) resistance by activating …

… assays were used to analyze the proliferation, apoptosis and gemcitabine (GEM) resistance
of pancreatic ductal adenocarcinoma (PDAC) cells. Xenograft model and IHC experiments …

… pancreatic ductal carcinoma cell lines were treated with continuous GEM to confirm the
hypothesis about GEM resistance in … ) did not induce GEM resistance, whereas the other two cell …

… Gemcitabine (GEM) resistance is one of the major causes of treatment failure in pancreatic
ductal adenocarcinoma … that MTA3 mediates the GEM resistance of PDAC and thus might be …

… Considering that overexpression of LAMC2 is associated with gemcitabine resistance in our
… of gemcitabine resistance in PC cells. Therefore, we examined the gemcitabine sensitivity of …

… in human pancreatic cancer cell lines and gemcitabine resistant pancreatic cancer cell lines
… GEO, and discovered a new gemcitabine resistant-related molecule in pancreatic cancer: …

… gemcitabine resistance, we divided postoperative patients into gemcitabine treatment
groups and non-gemcitabine … survival in gemcitabine treatment groups, but not in non-gemcitabine …

… gemcitabine resistance, as HK2 dimerization is enhanced in cells that do not respond to
gemcitabine… of HK2 enhanced the sensitivity of PDAC to gemcitabine. Similarly, in another study, …